Doyeon Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Doyeon Kim has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chan Woo Kang
Department of Internal Medicine Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine , Seoul 03722
1 shared publication - Cheol Ryong Ku
Endocrinology, Institute of Endocrine Research, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
1 shared publication - Eun Kyung Wang
Department of Internal Medicine, Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Republic of Korea
1 shared publication - Hye Ju Shin
Department of Clinical Drug Discovery & Development, Yonsei University College of Medicine, Seoul, Republic of Korea
1 shared publication - Ju Hun Oh
Department of Internal Medicine, Endocrinology, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Republic of Korea
1 shared publication - Jung Ho Nam
Endocrinology, Institute of Endocrine Research, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Obesity
- Vol. 2025 (1) , 4870532
Roux‐en‐Y Gastric Bypass Versus Single Anastomosis Duodeno–Ileal Bypass With Sleeve Gastrectomy: Different Mechanisms, Similar Outcomes
Objective: We aimed to compare the molecular mechanisms and metabolic outcomes of Roux‐en‐Y gastric bypass (RYGB) and single anastomosis duodeno–ileal bypass with sleeve gastrectomy (SADI‐S) using a preclinical model. Methods: Otsuka Long‐Evans Tokushima Fatty rats with diet‐induced obesity underwent RYGB, SADI‐S, or sham surgery. Metabolic parameters, including glucose tolerance, body weight, and 18F‐fluorodeoxyglucose biodistribution, were assessed at 1‐ and 2‐month postsurgery. The expression of Glucose transporter 1 (GLUT1) and glucose metabolism–related genes in intestinal segments was analyzed. Results: Although RYGB and SADI‐S yielded comparable improvements in glucose tolerance and body weight at 1 month postsurgery, they exerted their effects through distinct mechanisms. RYGB enhanced GLUT1‐mediated glucose excretion in the common limb, whereas SADI‐S upregulated the expression of the glycolytic genes Hk2, Fbp2, Aldob, and Ldha in the colon. Two months postsurgery, the observed metabolic improvements diminished despite sustained weight loss, which coincided with decreased expression of GLUT1 and glycolytic genes. Conclusions: RYGB and SADI‐S achieve similar benefits through distinct glucose handling pathways; however, these effects decline over time. Our data do not support the superiority of SADI‐S over RYGB, particularly given its higher complication rate, and instead highlight the need for strategies aimed at prolonging the therapeutic benefits of metabolic surgeries.
- 1 January 2025
- Published by Wiley in Journal of Obesity
- Vol. 2025 (1) , 4870532
Open AccessRoux‐en‐Y Gastric Bypass Versus Single Anastomosis Duodeno–Ileal Bypass With Sleeve Gastrectomy: Different Mechanisms, Similar Outcomes
Objective: We aimed to compare the molecular mechanisms and metabolic outcomes of Roux‐en‐Y gastric bypass (RYGB) and single anastomosis duodeno–ileal bypass with sleeve gastrectomy (SADI‐S) using a preclinical model. Methods: Otsuka Long‐Evans Tokushima Fatty rats with diet‐induced obesity underwent RYGB, SADI‐S, or sham surgery. Metabolic parameters, including glucose tolerance, body weight, and 18F‐fluorodeoxyglucose biodistribution, were assessed at 1‐ and 2‐month postsurgery. The expression of Glucose transporter 1 (GLUT1) and glucose metabolism–related genes in intestinal segments was analyzed. Results: Although RYGB and SADI‐S yielded comparable improvements in glucose tolerance and body weight at 1 month postsurgery, they exerted their effects through distinct mechanisms. RYGB enhanced GLUT1‐mediated glucose excretion in the common limb, whereas SADI‐S upregulated the expression of the glycolytic genes Hk2, Fbp2, Aldob, and Ldha in the colon. Two months postsurgery, the observed metabolic improvements diminished despite sustained weight loss, which coincided with decreased expression of GLUT1 and glycolytic genes. Conclusions: RYGB and SADI‐S achieve similar benefits through distinct glucose handling pathways; however, these effects decline over time. Our data do not support the superiority of SADI‐S over RYGB, particularly given its higher complication rate, and instead highlight the need for strategies aimed at prolonging the therapeutic benefits of metabolic surgeries.